309 related articles for article (PubMed ID: 29798908)
21. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
22. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.
Shayakhmetov DM; Li ZY; Ni S; Lieber A
Cancer Res; 2002 Feb; 62(4):1063-8. PubMed ID: 11861383
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic adenovirus based on serotype 3.
Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
[TBL] [Abstract][Full Text] [Related]
25. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.
Leja J; Yu D; Nilsson B; Gedda L; Zieba A; Hakkarainen T; Åkerström G; Öberg K; Giandomenico V; Essand M
Gene Ther; 2011 Nov; 18(11):1052-62. PubMed ID: 21490682
[TBL] [Abstract][Full Text] [Related]
27. Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy.
Wu C; Wei FK; Xu ZY; Wen RM; Chen JC; Wang JQ; Mao LJ
Front Biosci (Landmark Ed); 2021 Oct; 26(10):866-872. PubMed ID: 34719211
[TBL] [Abstract][Full Text] [Related]
28. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
[TBL] [Abstract][Full Text] [Related]
29. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.
Koizumi N; Mizuguchi H; Sakurai F; Yamaguchi T; Watanabe Y; Hayakawa T
J Virol; 2003 Dec; 77(24):13062-72. PubMed ID: 14645563
[TBL] [Abstract][Full Text] [Related]
30. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
31. M11: A Tropism-Modified Oncolytic Adenovirus Arming with a Tumor-Homing Peptide for Advanced Ovarian Cancer Therapies.
Li F; Yuan Y; Dai Y; Cheng T; Cao H; Yan D; Li Y; Sun Q; Huang X; Gao Q
Hum Gene Ther; 2022 Mar; 33(5-6):262-274. PubMed ID: 35018835
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
[TBL] [Abstract][Full Text] [Related]
33. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.
Choi JW; Kim HA; Nam K; Na Y; Yun CO; Kim S
J Control Release; 2015 Dec; 220(Pt B):691-703. PubMed ID: 26437261
[TBL] [Abstract][Full Text] [Related]
34. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.
Kanerva A; Wang M; Bauerschmitz GJ; Lam JT; Desmond RA; Bhoola SM; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
Mol Ther; 2002 Jun; 5(6):695-704. PubMed ID: 12027553
[TBL] [Abstract][Full Text] [Related]
35. Retargeted adenoviruses for radiation-guided gene delivery.
Kaliberov SA; Kaliberova LN; Yan H; Kapoor V; Hallahan DE
Cancer Gene Ther; 2016 Sep; 23(9):303-14. PubMed ID: 27492853
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.
Hensen LCM; Hoeben RC; Bots STF
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957644
[TBL] [Abstract][Full Text] [Related]
37. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
[TBL] [Abstract][Full Text] [Related]
38. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
Zheng S; Ulasov IV; Han Y; Tyler MA; Zhu ZB; Lesniak MS
J Gene Med; 2007 Mar; 9(3):151-60. PubMed ID: 17351980
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo.
Denby L; Work LM; Graham D; Hsu C; von Seggern DJ; Nicklin SA; Baker AH
Hum Gene Ther; 2004 Nov; 15(11):1054-64. PubMed ID: 15610606
[TBL] [Abstract][Full Text] [Related]
40. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Hakkarainen T; Särkioja M; Lehenkari P; Miettinen S; Ylikomi T; Suuronen R; Desmond RA; Kanerva A; Hemminki A
Hum Gene Ther; 2007 Jul; 18(7):627-41. PubMed ID: 17604566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
